Key issues in the role of peroxisome proliferator-activated receptor agonism and cell signaling in trichloroethylene toxicity

Environmental Health Perspectives

Volumn 114, Issue 9, 2006, Pages 1464-1470

  Keshava, Nagalakshmi ^a   Caldwell, Jane C ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Dichloroacetic acid; Peroxisome proliferator activated receptor; PPAR; Trichloroacetic acid; Trichloroethylene

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRICHLOROETHYLENE;

ARTICLE; CANCER SUSCEPTIBILITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEALTH HAZARD; KNOCKOUT MOUSE; LIVER TOXICITY; LIVER TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENICITY TESTS; ENVIRONMENTAL POLLUTANTS; GENE EXPRESSION REGULATION; HISTORY, 21ST CENTURY; HUMANS; LIVER NEOPLASMS; PPAR ALPHA; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TRICHLOROETHYLENE; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

EID: 33748188907     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.8693     Document Type: Article

References (107)

1. Anderson SP, Yoon L, Richard EB, Dunn CS, Cattley RC, Corton JC 2002. Delayed liver regeneration in peroxisome proliferator-activated receptor-α-null mice. Hepatology 36:544-554.
2. Asayama K, Sandhir R, Sheikh FG, Hayashibe H, Nakane T, Singh I. 1999. Increased peroxisomal fatty acid β-oxidation and enhanced expression of peroxisome proliferator-activated receptor-α in diabetic rat liver. Mol Cell Biochem 194:227-234.
3. Bannasch P. 1996. Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular, and metabolic changes. Proq Liver Dis 16:161-197.
4. Bannasch P, Nehrbass D, Kopp-Schneider A. 2001 Significance of hepatic preneoplasia for cancer chemoprevention. IARC Sci Publ 154:223-240.
5. Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. 2003a. Peroxisome proliferator-activated receptor α induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem 278:32852-32860.
6. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, et al. 2002. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22:717-726.
7. Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, et al. 2003b. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor α and γ target gene. J Biol Chem 278:13975-13983.
8. Bartosiewicz M, Jenkins D, Penn S, Emory J, Buckpitt A. 2001a. Unique gene expression patterns in liver and kidney associated with exposure to chemical toxicants. J Pharmacol Exp Ther 297(3):895-905.
9. Bartosiewicz M, Penn S, Buckpitt A. 2001b. Applications of gene arrays in environmental toxicology: fingerprints of gene regulation associated with cadmium chloride, benzo(a)pyrene, and trichloroethylene. Environ Health Perspect 109:71-74.
10. Berger J, Moller DE. 2002. The mechanisms of action of PPARs. Annu Rev Med 53:409-435.
11. Berger J, Wagner JA. 2002. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol Ther 4:163-174.
12. Booker LM, Habermacher GM, Jessie BC. Sun QC, Baumann AK, Amin M, et al. 2006. North American white mitochondrial haplogroups in prostate and renal cancer. J Ural 175(2)468-473.
13. Brisson D, Ledoux K, Bosse Y, St-Pierre J, Julien P, Perron P, et al. 2002. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 12:313-320.
14. Bull RJ. 2000. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ Health Perspect 108(suppl 2):241-259.
15. Caldwell JC, Keshava N. 2006. Key issues in the modes of action and effects of trichloroethylene metabolites for liver and kidney tumorigenesis. Environ Health Perspect 114:1457-1463.
16. Chao C, Youssef J, Rezaiekhaleigh M, Birnbaum LS, Badr M. 2002. Senescence-associated decline in hepatic peroxisomal enzyme activities corresponds with diminished levels of retinoid X receptor alpha, but not peroxisome proliferator-activated receptor alpha. Mech Ageing Dev 123:1469-1476.
17. Chen C, Hennig GE, Whiteley HE, Corton JC, Manautou JE. 2000. Peroxisome proliferator-activated receptor α-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. Toxicol Sci 57:338-344.
18. Chen C, Hennig GE, Whiteley HE, Manautou JE. 2002. Protection against acetaminophen hepatotoxicity by clofibrate pretreatment role of catalase induction. J Biochem Mol Toxicol 16:227-234.
19. Chiu WA, Caldwell JC, Keshava N, Scott CS. 2006. Key scientific issues in the health risk assessment of trichloroethylene. Environ Health Perspect 114:1445-1449.
20. Collier JM, Selmin O, Johnson PD, Runyan RB. 2003. Trichloroethylene effects on gene expression during cardiac development. Birth Defects Res A Clin Mol Teratol 67:488-495.
21. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. 1998. Peroxisome proliferator-activated receptor alphaisoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273:29577-29585.
22. Dufour JM, Vo MN, Bhattacharya N, Okita J, Okita R, Kim KH. 2003. Peroxisome proliferators disrupt retinoic acid receptor alpha signaling in the testis. Biol Reprod 68:1215-1224.
23. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. 2001. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142:4195-4202.
24. Eurlings PM, van der Kallen CJ, Geurts JM, Flavell DM, de Bruin TW. 2002. Identification of the PPARA locus on chromosome 22q13.3 as a modifier gene in familial combined hyperlipidemia. Mol Genet Metab 77:274-281.
25. Fan LQ, Coley J, Miller RT, Cattley RC, Corton JC. 2003. Opposing mechanisms of NADPH-cytochrome P450 oxidoreductase regulation by peroxisome proliferators. Biochem Pharmacol 66:949-950.
26. Fan LQ, You L, Brown-Borg H, Brown S, Edwards RJ, Corton JC. 2004. Regulation of phase I and phase II steroid metabolism enzymes by PPAR α activators. Toxicology 204:109-121.
27. Gazouli M, Yao ZX, Boujrad N, Corton JC, Culty M, Papadopoulos V. 2002. Effect of peroxisome proliferators on Leydig cell peripheral-type benzodiazepine receptor gene expression, hormone-stimulated cholesterol transport, and steroidogenesis: role of the peroxisome proliferator-activator receptor α. Endocrinology 143:2571-2583.
28. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La GL, et al. 2004. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585-2590.
29. Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, et al. 2001. PPAR-α-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50:2809-2814.
30. Harris IS, Treskov I, Rowley MW, Heximer S, Kaltenbronn K, Finck BN, et al. 2004. G-Protein signaling participates in the development of diabetic cardiomyopathy. Diabetes 53:3082-3090
31. Hasmall S, James N, Hedley K, Olsen K, Roberts R. 2001. Mouse hepatocyte response to peroxisome proliferators: dependency on hepatic nonparenchymal cells and peroxisome proliferator activated receptor α (PPARα). Arch Toxicol 75:357-361.
32. Hasmall S, Orphanides G, James N, Pennie W, Hedley K, Soames A, et al. 2002. Downregulation of lactoferrin by PPARalpha ligands: role in perturbation of hepatocyte proliferation and apoptosis. Toxicol Sci 68:304-313.
33. Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, et al. 2005. Role of peroxisome proliferator-activated receptor α (PPARα) in benzafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26(1):219-227.
34. Holden PR, Hasmall SC, James NH, West DR, Brindle RD, Gonzalez FJ, et al. 2000. Tumour necrosis factor α (TNFα): role in suppression of apoptosis by the peroxisome proliferator nafenopin. Cell Mol Biol (Noisy-le-grand) 46:29-39.
35. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. 2003. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 54:131-152.
36. Huss JM, Kelly DP. 2004. Nuclear receptor signaling and cardiac energetics. Circ Res 95:568-578.
37. Huss JM, Kelly DP. 2005. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115:547-555.
38. Huss JM, Torra IP, Staels B, Giguere V, Kelly DF. 2004. Estrogen-related receptor alpha directs peroxisome proliferation-activated receptor α signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 24:9079-9091.
39. International Agency for Research on Cancer, 1996. Some pharmaceutical drugs. IARC Monogr Eval Carcinog Risks Hum 66:514.
40. Jalouli M, Carlsson L, Ameen C, Linden D, Ljungberg A, Michalik L, et al. 2003. Sex difference in hepatic peroxisome proliferator-activated receptor α expression: influence of pituitary and gonadal hormones. Endocrinology 144:101-109.
41. Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, Staels B, et al. 2002. Peroxisome proliferator-activated receptor α gene regulates left ventricular growth in response to exercise and hypertension, Circulation 105:950-955.
42. Jia Y, Qi C, Zhang Z, Hashimoto T, Rao MS, Huyghe S, et al. 2003. Overexpression of peroxisome proliferator-activated receptor-α (PPARα)-regulated genes in liver in the absence of peroxisome proliferation in mice deficient in both L- and D-forms of enoyl-CoA hydratase/dehydrogenase enzymes of peroxisomal β-oxidation system. J Biol Chem 278:47232-47239.
43. Jiang YJ, Liu B, Xu FY, Gartshore J, Taylor WA, Halayko AJ, et al. 2004. Stimulation of cardiac cardiolipin biosynthesis by PPARα activation. J Lipid Res 45:244-252.
44. Jove M, Salla J, Planavila A, Cabrero A, Michalik L, Wahli W, et al. 2004. Impaired expression of NADH dehydrogenase subunit 1 and PPARγ coactivator-1 in skeletal muscle of ZDF rats: restoration by troglitazone. J Lipid Res 45:113-123.
45. Kersten S, Desvergne B, Wahli W. 2000. Roles of PPARs in health and disease. Nature 405:421-424.
46. Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, et al. 2001. The peroxisome proliferator-activated receptor α regulates amino acid metabolism. FASEB J 15:1971-1978.
47. Kim HS, Saito K, Ishizuka M, Kazusaka A, Fujita S. 2003. Short period exposure to di-(2-ethylhexyl) phthalate regulates testosterone metabolism in testis of prepubertal rats. Arch Toxicol 77(8):446-451.
48. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, et al. 2003. PPARα agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 33:655-780.
49. Klotz L, Hacker HJ, Klingmuller D, Bannasch P, Pfeifer U, Dombrowski F. 2000. Hepatocellular alterations after intraportal transplantation of ovarian tissue in ovariectomized rats. Am J Pathol 156:1613-1626.
50. Komar CM, Braissant O, Wahli W, Curry TE Jr. 2001. Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology 142:4831-4839
51. Lacquemant C, Lepretre F, Pineda Torra I, Manraj M, Charpentier G, Ruiz J, et al. 2000. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab 26:393-401
52. Laughter AR, Dunn CS, Swanson CL, Howroyd P, Cattley RC, Corton JC. 2004. Role of the peroxisome proliferator-activated receptor α (PPARα) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver. Toxicology 203:83-98.
53. Lewitt MS, Brismar K, Wang J, Wivall-Helleryd IL, Sindelar P, Gonzalez FJ, et al. 2001. Responses of insulin-like growth factor (IGF)-1 and IGF-binding proteins to nutritional status in peroxisome proliferator-activated receptor-α knockout mice. Growth Horm IGF Res 11:303-313.
54. Liu K, Xu L, Berger JP, Macnaul KL, Zhou G, Doebber TW, et al. 2005. Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia. J Med Chem 48:2262-2265.
55. Liu Z, Uesaka T, Watanabe H, Kato N. 2001. High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin. Int J Oncol 19:1009-1014.
56. Macdonald N, Chevalier S, Tonge R, Davison M, Rowlinson R, Young J, et al. 2001. Quantitative proteomic analysis of mouse liver response to the peroxisome proliferator diethyl-hexylphthalate (DEHP). Arch Toxicol 75:415-424.
57. Maloney EK, Waxman DJ. 1999. trans-Activation of PPARalpha and PPARγ by structurally diverse environmental chemicals. Toxicol Appl Pharmacol 161(2):209-218.
58. Marsman DS, Cattley RC, Conway JG, Popp JA. 1988. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res 48:6739-6744.
59. Meyer K, Lee JS, Dyck PA, Cao WQ, Rao MS, Thorgeirsson SS, et al. 2003. Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. Carcinogenesis 24:975-984.
60. Michalik L, Desvergne B, Dreyer C, Gavillet M, Laurini RN, Wahli W. 2002. PPAR expression and function during vertebrate development. Int J Dev Biol 46:105-114.
61. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, et al. 2001. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J Cell Biol 154:799-814
62. Miller RT, Scappino LA, Long SM, Corton JC. 2001. Role of thyroid hormones in hepatic effects of peroxisome proliferators. Toxicol Pathol 29:149-155.
63. Moennikes O, Stahl S, Bannasch P, Buchmann A, Schwarz M. 2003. WY-14,643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice. Carcinogenesis 24:1561-1565.
64. Moller DE, Berger JP. 2003. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 27(suppl 3):S17-S21
65. Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, et al. 2002. Peroxisome proliferator-activated receptor-α regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 51:901-909
66. Nakajima T, Kamijo Y, Usuda N, Liang Y, Fukushima Y, Kametani K, et al. 2000. Sex-dependent regulation of hepatic peroxisome proliferation in mice by trichloroethylene via peroxisome proliferator-activated receptor α (PPARα). Carcinogenesis 21:677-682.
67. Nohammer C, Brunner F, Wolkart G, Staber PB, Steyrer E, Gonzalez FJ, et al. 2003. Myocardial dysfunction and male mortality in peroxisome proliferator-activated receptor alpha knockout mice overexpressing lipoprotein lipase in muscle. Lab Invest 83:259-269.
68. O'Brien ML, Twaroski TP, Cunningham ML, Glauert HP, Spear BT. 2001. Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters. Toxicol Sci 60:271-278.
69. Pon DA, Mater MK, Thelen AP, Peters JM, Gonzales FJ, Jump DB. 2000. Evidence against the peroxisome proliferator-activated receptor α (PPARα) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription. J Lipid Res 41:742-751.
70. Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, Barlow NJ, et al 2000. The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. Toxicol Sci 58:339-349.
71. Parzefall W, Berger W, Kainzbauer E, Teufelhofer O, Schulte-Hermann R, Thurman RG. 2001. Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes. Carcinogenesis 22:519-523.
72. Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG, 2000. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 21:823-826.
73. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, et al. 2005. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 102:719-724.
74. Poirier H, Niot I, Monnot MC, Braissant O, Meunier-Durmort C, Costet P, et al. 2001. Differential involvement of peroxisome-proliferator-activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochem J 355:481-488.
75. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SO, et al. 1998. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 20:291-293.
76. Poole M, Bridgers K, Alexson SE, Carton JC. 2001. Altered expression of the carboxylesterases ES-4 and ES-10 by peroxisome proliferator chemicals Toxicology 165:109-119.
77. Reddy JK, Rao MS. 1989. Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcino-genesis. Mutat Res 214:63-68.
78. Ring JA, Ghabrial H, Ching MS, Smallwood RA, Morgan DJ. 1999. Fetal hepatic drug elimination. Pharmacol Ther 84:429-445.
79. Ripp SL, Falkner KC, Pendleton ML, Tamasi V, Prough RA. 2003. Regulation of CYP2C11 by dehydroepiandrosterone and peroxisome proliferators: identification of the negative regulatory region of the gene. Mol Pharmacol 64:113-122.
80. Roberts RA, Chevalier S, Hasmall SC, James NH, Cosulich SC, Macdonald N. 2002. PPAR α and the regulation of cell division and apoptosis. Toxicology 181-182:167-170.
81. Robitaille J, Brouillette C, Houde A, Lemieux S, Perusse L, Tchernof A, et al. 2004. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 49:482-489.
82. Rusyn I, Kadiiska MB, Dikalova A, Kono H, Yin M, Tsuchiya K, et al 2001. Phthalates rapidly increase production of reactive oxygen species in vivo: role of Kupffer cells, Mol Pharmacol 59:744-750.
83. Rusyn I, Rose ML, Bojes HK, Thurman RG. 2000. Novel role of oxidants in the molecular mechanism of action of peroxisome proliferators. Antioxid Redox Signal 2:607-621.
84. Sandhu MS, Dunger DB, Giovannucci EL. 2002. Insulin, insulin-like growth factor-1 (IGF-1), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94:972-980.
85. Scatena R, Bottoni P, Vincenzoni F, Messana I, Martorana GE, Nocca G, et al. 2003. Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a poroxisome proliferator. Chem Res Toxicol 16:1440-1447.
86. Seree E, Villard PH, Pascussi JM, Pineau T, Maurel P, Nguyen OB, et al. 2004. Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites. Gastroenterology 127:1436-1445.
87. Shankar K, Vaidya VS, Corton JC, Bucci TJ, Liu J, Waalkes MP, et al, 2003. Activation of PPAR-α in streptozotocin-induced diabetes is essential for resistance against acetaminophen toxicity. FASEB J 17:1748-1750.
88. Simpson AE, Brammar WJ, Pratten MK, Cockcroft N, Elcombe CR. 1996. Placental transfer of the hypolipidemic drug, clofibrate, induces CYP4A expression in 18.5-day fetal rats. Drug Metab Dispos 24:547-554.
89. Simpson AE, Brammar WJ, Pratten MK, Elcombe CR. 1995. Translactational induction of CYP4A expression in 10.5-day neonatal rats by the hypolipidemic drug clofibrate. Biochem Pharmacol 50:2021-2032
90. Sinal CJ, Yoon M, Gonzalez FJ 2001. Antagonism of the actions of peroxisome proliferator-activated receptor-α by bile acids. J Biol Chem 276:47154-47162.
91. Thompson HJ, Jiang W, Zhu Z. 1999, Mechanisms by which energy restriction inhibits carcinogenosis. Adv Exp Med Biol 470:77-84.
92. U.S. EPA. 2001. Trichloroethylene Health Risk Assessment: Synthesis and Characterization. External Review Draft. EPA/600/P-01/002A. Washington, DC:U.S. Environmental Protection Agency, Office of Research and Development.
93. Valles EG, Laughter AR, Dunn CS, Cannelle S, Swanson CL, Cattley RC, et al. 2003. Role of the peroxisome proliferator-activated receptor α in responses to diisononyl phthalate. Toxicology 191:211-225.
94. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, et al. 2000. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipo-proteinemia. J Lipid Res 41:945-952.
95. Vosper H, Khoudoli GA, Graham TL, Palmer CN. 2002. Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Ther 95:47-62.
96. Walgren JE, Kurtz OT, McMillan JM. 2000a. The effect of the trichloroethylene metabolites trichloroacetate and dichloroacetate on peroxisome proliferation and DNA synthesis in cultured human hapatocytes. Cell Biol Toxicol 16:257-273.
97. Walgren JE, Kurtz DT, McMillan JM. 2000b. Expression of PPARα in human hepatocytes and activation by trichloroacetate and dichloroacetate. Res Commun Mol Pathol Pharmacol 108:116-132.
98. Wartenberg D, Reyner D, Scott CS. 2000. Trichloroethylene and cancer: epidemiologic evidence. Environ Health Perspect 108(suppl 2):161-176.
99. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, et al. 2000, Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age-dependent cardiac toxicity. J Biol Chem 275:22293-22299.
100. Xu S, Zhu BT, Turan V, Rusyn I, Thurman R, Peters JM, et al. 2001. PPARα-dependent induction of liver microsomal esterification of estradiol and testosterone by a prototypical peroxisome proliferator. Endocrinology 142:3554-3557.
101. Youssef J, Badr M. 2002. Enhanced hepatocarcinogenicity due to agonists of peroxisome proliferator-activated receptors in senescent rats: role of peroxisome proliferation, cell proliferation, and apoptosis. Sci World J 2:1491-1500.
102. Youssef JA, Bouziane M, Badr MZ. 2003. Age-dependent effects of nongenotoxic hepatocarcinogens on liver apoptosis in vivo, Mech Ageing Dev 124:333-340.
103. Zhou S, Wallace KB. 1999. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol Sci 48:82-89.
104. Zhou YC, Davey HW, McLachlan MJ, Xie T, Waxman DJ. 2002. Elevated basal expression of liver peroxisomal beta-oxidation enzymes and CYP4A microsomal fatty acid omega-hydroxylase in STAT5b(-/-) mice: cross-talk in vivo between peroxisome proliferator-activated receptor and signal transducer and activator of transcription signaling pathways. Toxicol Appl Pharmacol 182:1-10.
105. Zhou YC, Waxman DJ. 1998. Activation of peroxisome proliferator-activated receptors by chlorinated hydrocarbons and endogenous steroids. Environ Health Perspect 106(suppl 4): 983-988.
106. Zhou YC, Waxman DJ. 1999. Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor alpha (PPARα) signaling pathways. Growth hormone inhibition of PPARalpha transcriptional activity mediated by stat5b. J Biol Chem 274(5):2672-2681.
107. Zhu Y, Qi C, Jain S, Le Beau MM, Espinosa R III, Atkins GB, et al. 1999. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci USA 96:10848-10853.